Arix Pegs LogicBio's Technology As 'Occam's Razor' Of Gene Therapy

Gene therapy startup LogicBio, with input from Arix Biosciences, has raised almost $50m via a series B financing round; it plans to use the cash to continue development of a potential novel alternative to traditional gene therapy.

DNA

LogicBio Therapeutics has raised $45m in a series B financing, led by Arix Biosciences, bringing to $50m the total the recently launched firm has raised to complete preclinical development of an innovative gene therapy platform for pediatric diseases and move lead programs into clinical studies.

Arix's CEO Joe Anderson told Scrip that Arix had "identified limitations with traditional gene therapy and the need for gene...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.